Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.

Community Practice Connections™: Emerging Paradigm Shifts in Renal Cell Carcinoma: A Critical Assessment of Adjuvant Treatment Data

Release Date: April 30, 2018
Expiration Date: April 30, 2019
Media: Internet - based


Activity Overview

Renal cell carcinoma (RCC) remains one of most difficult to treat of the solid tumors. However, RCC treatment is also one of the most rapidly evolving fields in oncology. New data suggest impending changes in both early-stage and metastatic RCC, including novel indications, combination approaches, and optimized adjuvant strategies. Presently, the use of adjuvant therapy for patients with RCC who are at high risk for recurrence after nephrectomy remains an area of controversy.

This activity features video interviews with renowned experts who critically review and discuss aspects of adjuvant therapy for RCC that are important to cancer care providers, including current data on adjuvant therapy, risk assessment, and patient selection; key areas of controversy and clinical uncertainty; ongoing clinical trials; and emerging therapeutic options.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.

CME Activity Table of Contents

  • Introduction
  • Module 1: Risk Assessment and Patient Selection to Identify Patients for Adjuvant Treatment
  • Module 2: Assessing Key Questions in the Field Related to Adjuvant Management of Renal Cell Carcinoma
  • Module 3: A Forward Look at the Adjuvant Setting
  • Module 4: Key Takeaways

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is directed toward urologists, medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with RCC will be invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Substantiate treatment decisions in the management of RCC at key decision points along the disease continuum based on the most pertinent clinical trial evidence for targeted therapy
  • Integrate knowledge of patient selection, single-agent, and combination strategies in the context of mechanisms of action, kinetics of response, best practices in monitoring, and key information that informs adjuvant treatment in the care of patients with RCC
  • Manage treatment-related toxicities as a component of therapeutic decision making in adjuvant treatment settings for patients with RCC
  • Evaluate recent clinical trial data, key ongoing trials, and how emerging adjuvant strategies may further impact the RCC treatment landscape

Faculty, Staff, and Planners' Disclosures


Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Disclosure:Grant/Research Support: Peloton Therapeutics, Bristol-Meyers Squibb, Argos Therapeutics, Exelixis, Inc, Merck; Consultant: Pfizer, CM Therapeutics.

Lauren C. Harshman, MD
Assistant Professor,
Medicine, Harvard Medical School
Assistant Professor,
Medical Oncology,
Dana-Farber Cancer Institute
Boston, Massachusetts

Disclosure: Grant/Research Support: Bayer, Genentech, Dendreon/Valeant, Pfizer, Medivation/Astellas Pharma, Merck, Bristol-Meyers Squibb, Janssen, Sotio, Takeda; Consultant: Bayer, Exelixis, Genentech, Dendreon/Valeant, Pfizer, Medivation/Astellas Pharma, Kew Group, Theragene, Corvus Pharmaceuticals, Merck.

Bradley C. Leibovich, MD, FACS
Chair, Department of Urology
David C. Utz, MD, Professor of Urology
Mayo Clinic
Rochester, Minnesota

Disclosure: No relevant financial relationships with commercial interests to disclose.

Alain Ravaud, MD, PhD
Professor of Medical Oncology
Head of Department of Medical Oncology at Bordeaux University Hospital
Bordeaux, France

Disclosure: Consultant: Advisory Board for Pfizer, Novartis, Bristol-Meyers Squibb, and Merck.

Brian I. Rini, MD, FACP
Professor of Medicine, Lerner College of Medicine
Leader, GU Program
Department of Hematology and Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Disclosure: Grant/Research Support: Bristol-Meyers Squibb, Pfizer, Roche, Merck; Consultant: Pfizer.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse Recap™

PER Pulse Recap (1 of 3)

This first of 3 PER Pulse™ Recaps summarizing the online program focuses on the faculty’s answers to questions about assessing recurrence risk and selecting patients for adjuvant RCC therapy, during which they discussed:
  • Available strategies for identifying high-risk RCC after resection, including gold standards for pathology reports
  • Urologist versus oncologist perspectives on criteria for assessing high risk
  • Best practices for selecting patients for adjuvant tyrosine kinase inhibitor therapy based on published phase III studies
  • Multidisciplinary approaches to improve care for patients with high-risk RCC

PER Pulse Recap (2 of 3)

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on the faculty’s responses to unanswered questions about and controversies over data from recent clinical trials for the adjuvant treatment of RCC, during which they discussed:
  • Personal perspectives on the role and use of adjuvant therapy for RCC in today’s practice
  • Key data from recent critical studies in the field, including ASSURE, ProtecT, and S-TRAC, their conflicting results, and how various aspects of these trials may have affected their outcomes
  • Whether longer disease-free survival versus overall survival derives benefit for patients in the adjuvant setting

PER Pulse Recap (3 of 3)

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on faculty’s answers to questions about the future of adjuvant treatment for RCC, during which they discussed:
  • The outlook on patient selection and risk assessment for adjuvant RCC therapy
  • Key ongoing clinical trials of adjuvant tyrosine kinase inhibitor therapy for RCC and how they may shape the current treatment landscape
  • The rationale for using immunotherapy in the setting of adjuvant RCC treatment

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By